BHMT gene polymorphisms as risk factors for cleft lip and cleft palate in a Chinese population

Ying Hu1, Erjun Chen, Yue Mu

  • 1Beijing Stomatological Hospital, Capital Medical University, Beijing 100050, China. huying_369@yahoo.com.cn

Insights

Genetic variations in the betaine-homocysteine methyltransferase (BHMT) gene may increase the risk of nonsyndromic cleft lip with or without cleft palate (NSCL/P). Specifically, the BHMT rs3797546 polymorphism is associated with NSCL/P in a recessive manner.

Area of Science:

  • Genetics
  • Developmental Biology
  • Public Health

Background:

  • Maternal folic acid intake is linked to nonsyndromic cleft lip with or without cleft palate (NSCL/P) risk.
  • Genetic factors may also play a role in NSCL/P etiology.

Purpose of the Study:

  • To investigate the association between genetic variations in the betaine-homocysteine methyltransferase (BHMT) gene and NSCL/P.
  • To explore the role of specific BHMT single nucleotide polymorphisms (SNPs) in NSCL/P susceptibility.

Main Methods:

  • Genotyping of three BHMT SNPs (rs651852, rs3797546, rs3733890) using real-time PCR.
  • Case-control study involving 166 NSCL/P patients and 285 healthy controls.

Main Results:

  • No significant association was found for BHMT SNPs rs651852 and rs3733890 with NSCL/P.
  • The CC genotype of BHMT SNP rs3797546 showed a higher prevalence in NSCL/P patients compared to TT+CT genotypes (P=0.020, OR=2.10).

Conclusions:

  • The BHMT gene polymorphism rs3797546 may confer a genetic risk for NSCL/P.
  • This association appears to be recessive, suggesting a potential genetic predisposition to NSCL/P.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Lingo01:11

Genetic Lingo

Overview
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Probability Laws01:49

Probability Laws

Overview
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...